Is Prostate Cancer Really Life-Threatening in 2026?

Prostate cancer generally progresses slowly and does not often threaten life quickly. For people in Korea diagnosed between 2019 and 2023, the 5-year relative survival rate is 96.9%. However, this is a nationwide statistic, not a prediction of any individual's outcome.

핵심 요약

• Korea's 5-year relative survival rate for prostate cancer is 96.9%, up 37.7 percentage points from 1993–1995 (National Cancer Registration Statistics 2019–2023, Central Cancer Registry, National Cancer Center Korea).
• The 5-year relative survival rate under the US SEER statistics is 98.2% (SEER 2016–2022). Both figures are nationwide statistics, not results from any specific hospital.
• Prostate cancer often progresses slowly, making it one of the rare cancers for which active surveillance—monitoring at set intervals without treatment—is included among standard options.
• Treatment decisions are based not only on stage but on a risk group combining PSA level, Gleason score (grade group), and stage, together with age, life expectancy, and coexisting conditions.
• Even at the stage of bone metastasis, long-term disease control centered on hormone therapy is possible, but this stage is not one where the treatment goal is a cure.

전립선암은 정말 생명을 위협하는 병인가요?

• This varies greatly depending on risk group and stage. When found at a localized stage, patients can choose among surgery, radiation therapy, and active surveillance, and the national statistics put the 5-year survival rate as high as 96.9% (National Cancer Registration Statistics 2019–2023). However, this figure is a population-level average and does not predict any individual's outcome.
• Risk groups are divided into low, intermediate, and high risk. Low risk refers to cases with a low PSA level, the lowest grade group, and disease confined to a small area within the prostate. Cases with lymph node involvement are classified as locally advanced, while spread to bone or other organs is classified as metastatic.
• Even at the metastatic stage, long-term control is achievable with a standard approach centered on hormone therapy that blocks male hormones, combined from the outset with stronger anti-androgen agents or chemotherapy. If hormone therapy stops working, radioligand therapy (targeting PSMA) or other drug classes are considered.

생존율이 높아진 이유는 무엇인가요?

• The rise in survival rates is explained in part by the widespread use of the PSA blood test, which has increased the proportion of cases diagnosed at a localized stage.
• Step 1: If the PSA level is elevated or a digital rectal exam finds an abnormality, a prostate MRI is performed first. Step 2: If the MRI shows a suspicious area, an MRI-fusion biopsy is performed targeting that site. Step 3: The biopsy yields a Gleason score and grade group (1 to 5). Step 4: MRI is used to check for invasion of the prostate capsule, and if the risk group is high, a bone scan or PSMA PET is used to check for metastasis. Step 5: These results are combined to determine the risk group and discuss the direction of treatment.
• This diagnostic framework supports early detection and precise risk-group classification, helping avoid overtreatment of slow-growing cancers while broadening the options for intervening at the appropriate time when needed.

치료를 받으면 어떤 변화가 나타날 수 있나요?

• The changes that occur differ depending on the treatment chosen, and there is individual variation. Robotic radical prostatectomy typically involves a 5–7 day hospital stay, and nearly all patients experience urinary incontinence for some period after surgery, with recovery generally occurring over several months.
• With radiation therapy and particle therapy, urinary symptoms and changes in bowel habits are common during treatment and usually settle within a few weeks after treatment ends, but in rare cases, late reactions in the bladder or bowel can appear months to years later, so any symptoms should be reported to the medical team.
• Hormone therapy is accompanied by changes such as hot flashes, reduced libido, muscle loss, and decreased bone density, so exercise and bone density checks are recommended alongside treatment. Carbon-ion (heavy particle) therapy has been available in Korea since 2023, and for localized prostate cancer it is typically completed in around 12 sessions, though eligibility depends on prior radiation history or the presence of an artificial hip joint.

자주 묻는 질문 — 적극적 감시는 위험하지 않나요?

For the low-risk group, active surveillance is a standard option. Changes are monitored through PSA tests, MRI, and repeat biopsy if needed at set intervals, and treatment is initiated if signs of progression appear. This approach can be chosen when the burden of side effects such as incontinence and reduced sexual function may outweigh the benefit of treatment, but it is only feasible if the patient can reliably attend the scheduled tests.

자주 묻는 질문 — 뼈로 전이된 뒤에도 치료가 되나요?

Metastatic prostate cancer can be controlled for a long time with treatment centered on hormone therapy. Combining drugs from the start has become the standard approach, used together with bone-protecting agents and radiation therapy to reduce pain. However, this stage is not one where the treatment goal is a cure, and if a genetic change such as BRCA is identified, a matching targeted therapy is considered.

출처와 유의사항

• This article was written based on general information from the National Cancer Registration Statistics 2019–2023 (Central Cancer Registry, National Cancer Center Korea), SEER 2016–2022, the National Cancer Information Center, and NCCN patient-level guidelines.
• This content is intended to provide general medical information, and the actual diagnosis, treatment methods, and outcomes may vary depending on the individual's condition. Accurate diagnosis and treatment should always be determined through consultation with a medical professional.